23ME610 is under clinical development by 23andMe Holding and currently in Phase II for Metastatic Renal Cell Carcinoma. According to GlobalData, Phase II drugs for Metastatic Renal Cell Carcinoma have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how 23ME610’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
23ME610 overview
23ME610 is under development for the treatment of locally advanced or metastatic solid malignancies including metastatic clear cell renal cell carcinoma, merkel cell carcinoma, epithelial ovarian, fallopian tube, primary peritoneal carcinoma, neuroendocrine cancers including small cell lung cancer and microsatellite instability-high (MSI-H) or tumor mutational burden-high (TMB-H) cancers. The therapeutic candidate comprises of a fully humanized IgG1 antibody which acts by targeting CD200R1. It is administered through intravenous route.
23AndMe Holding overview
23andMe Holding provides genetic test solutions to study ancestry, genealogy, and inherited traits that markets its data into categorized and searchable form to researchers. The company is headquartered in South San Francisco, California, the US.
For a complete picture of 23ME610’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
